Skip to content

A Study to Assess Total Symptoms in the Homoeopathic Management of Chronic Urticaria Among Adults

Effectiveness of Totality of Symptoms in Homoeopathic Management of Chronic Urticaria Among Adults-A Non- Controlled Experimental Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112200
Enrollment
39
Registered
2026-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L509- Urticaria, unspecified

Interventions

Intervention1: HOMOEOPATHIC MANAGEMENT: Individualized Homoeopathic Medicines Dose as per requirement of individual patient Frequency as per requirement of individual patient Route of administration o

Sponsors

Dr GD Pol Foundation YMT Homoeopathic Medical College Hospital and PG Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient of adult age group 18-50 years Patients of both sexes with chronic urticaria

Exclusion criteria

Exclusion criteria: Patients who are with suspected systemic hypersensitivity. Patients having any allergic systemic co-morbidities. Patients who are taking any other medication for any other aliment or for chronic urticaria in the last 3 months. Patients having other conservative treatment for chronic Urticaria (medication like-NSAIDs, pain killers or other pharmacological agents to manage symptoms). Patients who are suspected immunocompromised. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Urticaria Activity Score 7Timepoint: Baseline, 1 month, 3 month, 6 MONTHS

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Chintan Mehta

Dr.G.D.Pol Foundation, Y.M.T. Homoeopathic Medical College, Hospital and P.G. Institute

snehom5@gmail.com9322506976

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026